Glucosamine and chondroitin for knee osteoarthritis: A double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens

Annals of the Rheumatic Diseases

Volumn 74, Issue 5, 2015, Pages 851-858

  Fransen, Marlene ^a,f   Agaliotis, Maria ^a,f   Nairn, Lillias ^a,f   Votrubec, Milana ^b   Bridgett, Lisa ^a,f   Su, Steve ^c,f   Jan, Stephen ^a,f   March, Lyn ^a,f   Edmonds, John ^d,f   Norton, Robyn ^a,f   Woodward, Mark ^a   Day, Richard ^e,f   Buckland Wright, Chris ^f   Bridges Webb, Charles ^f   Heritier, Stephane ^f   Jones, Graeme ^f   Sambrook, Phillip ^f   Speechly, Catherine ^f   Vignon, Eric ^f   Jovanovic, Gorica ^g   Jeram, Shila ^g   Dowd, Mitchell ^g   Champion, Mandy ^g   Grealy, Sarah ^g   Watson, Deanne ^g   Vrataric, Anton ^f   Johnson, Cecil ^f   White, Rose ^f   O'Connell, Paul ^f   Milwraith, Fay ^h   Kennedy, Danielle ^h   Faulkes, Christine ^h   Bulton, Olivia ^h   Johnson, Kathleen ⁱ   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b Sydney Campus University of Notre Dame   (Australia)

^c Biostatistics   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f Royal Prince Alfred Hospital ^*  (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h ST GEORGE HOSPITAL   (Australia)

ⁱ North Shore Radiology   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; GLUCOSAMINE SULFATE; PLACEBO; GLUCOSAMINE;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; BODY MASS; CHRONIC PAIN; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; JOINT CAVITY; KNEE OSTEOARTHRITIS; KNEE PAIN; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SELF REPORT; SEX DIFFERENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; DIETARY SUPPLEMENT; KNEE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; RADIOGRAPHY;

AGED; CHONDROITIN SULFATES; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSAMINE; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; TREATMENT OUTCOME;

EID: 84926454571     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203954     Document Type: Article

References (39)

1. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull WHO 2003; 81:646-56.
2. Vos T, Flaxman AD, Naghavi M, et al Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2163-96.
3. Busija L, Bridgett L, Williams S., et al. Burden of musculoskeletal conditions: osteoarthritis. Best Pract Res Clin Rheumatol 2010; 24:757-69.
4. 45andUP Study. The 45 and UP Study Data Book. April 2010 release. 2010.
5. Towheed T, Maxwell L, Anastassiades T.P., et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2009;(4).
6. Reichenbach S, Sterchi R, Scherer M., et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007; 146:580-90.
7. Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 2010; 18:S28-31.
8. Clegg DO, Reda DJ, Harris C.L., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354:795-808.
9. Sawitzke AD, Shi H, Finco M.F., et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008; 58:3183-91.
10. Zhang W, Nuki G, Moskowitz R.W., et al. OARS recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18:476-99.
11. Conaghan PG, Dickson J, Grant RG Care and management of osteoarthritis in adults: summary of NICE guidance. BMJ 2008; 336:502-3.
12. Buckland-Wright J.C., Ward RJ, Peterfy C, et al Reproducibility of the semi-flexed (MTP) radiographic knee position and automated measurements of medial tibiofemoral joint space width in a multicentre clinical trial of knee osteoarthritis. J Rheumatol 2004; 31:1588-97.
13. Buckland-Wright J.C., Wolfe F, Ward R.J., et al. Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy, of standing extended, semiflexed (MTP), and Schuss views. J Rheumatol 1999; 26:2664-74.
14. Conrozier T, Mathieu P, Piperno M., et al. Selection of knee radiographs for trials of structure-modifying drugs in patients with knee osteoarthritis. Arthritis Rheum 2005; 52:1411-17.
15. Sangha O, Stucki G, Liang M.H., et al. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003; 49:156-63.
16. Bellamy N, Buchanan WW, Goldsmith C.H., et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15:1833-40.
17. Gandhi SK, Salmon JW, Zhao S.Z., et al. Psychometric evaluation of the 12-item short-form health survey (SF-12) in osteoarthritis and rheumatoid arthritis clinical trials. Clinical Therapeutics 2001; 23:1080-98.
18. Grace EM, Gerecz EM, Kassam Y.B., et al. 50-foot walking time: critical assessment of an outcome measure in clinical therapeutic trials of antirheumatic drugs. Br J Rheumatol 1988; 27:372-4.
19. Helio Le Graverand M-P, Vignon EP, Brandt KD, et al. Head-to-head comparison of the Lyon Schuss and fixed flexion radiographic techniques. Long-term reproducibility in normal knees and sensitivity to change in osteoarthritic knees. Ann Rheum Dis 2008; 67:1562-6.
20. Vignon E, Brandt KD, Mercier C, et al Alignment of the medial tibial plateau affects the rate of joint space narrowing in the osteoarthritic knee. Osteoarthritis Cartilage 2010; 18:1436-40.
21. Kellgren JH, Lawrence JS Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16:494-502.
22. Raynauld JP, Martel-Pelletier J, Haraoui B., et al. Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation. Ann Rheum Dis 2011; 70:1382-8.
23. Altman RD. Glucosamine therapy for knee osteoarthritis: pharmacokinetic considerations. Expert Rev Clin Pharmacol 2009; 2:359-71.
24. Sawitzke AD, Shi H, Finco M.F., et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010; 69:1459-64.
25. Pavelka K, Gatterova J, Olejarova M., et al. Glucosamine sulphate use and delay of progression of knee osteoarthritis. A 3 year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162:2113-23.
26. Reginster JY, Deroisy R, Rovati L.C., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357:251-6.
27. Hawker GA, Stewart L, French M.R., et al. Understanding the pain experience in hip and knee osteoarthritis - an OARSI/OMERACT initiative. Osteoarthritis Cart 2008; 16:415-22.
28. Moher D, Hopewell S, Schulz K.F., et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trial. BMJ 2010; 340:c869.
29. Wandel S, Juni P, Tendal B., et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341: c4675.
30. Tat SK, Pelletier JP, Verges J, et al Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subcondral bone osteoblasts: a basic science study. Arthritis Res Ther 2007; 9:R117.
31. Hochberg MC, Clegg DO Potential effects of chondroitin sulfate on joint swelling: a GAIT report. Osteoarthritis Cart 2008; 16:S22-4.
32. Wildi LM, Raynauld J-P, Martel-Pelletier J, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011; 70:982-9.
33. Huskisson EC. Glucosamine and chondroitin for osteoarthritis. J Int Med Res 2008; 36:1161-79.
34. Aghazadeh-Habashi A., Jamali G. The glucosamine controversy; a pharmacokinetic issue. J Pharm Pharmaceut Sci 2011; 14:264-73.
35. Miller KL, Clegg DO Glucosamine and chondroitin sulfate. Rheum Dis Clin N Am 2011; 37:103-18.
36. Hoffer LJ, Kaplan LN, Hamadeh M.J., et al. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism 2001; 50:767-70.
37. van der Kraan PM, Vitters EL, de Vries BJ, et al. High susceptibility of human articular cartilage glycosaminoglycan synthesis to changes in inorganic sulfate availability. J Orthop Res 1990; 8:565-71.
38. Bruyere O, Richy F, Reginster JY Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study. Ann Rheum Dis 2005; 64:1727-30.
39. Cicuttini FM, Wluka AE, Wang Y, et al Longitudinal study of changes in tibial and femoral cartilage in knee osteoarthritis. Arthritis Rheum 2004; 50:94-7.